Advanced Solid Tumors Clinical Trials

189 recruiting

Advanced Solid Tumors Trials at a Glance

227 actively recruiting trials for advanced solid tumors are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 1 with 201 trials, with the heaviest enrollment activity in Houston, Shanghai, and San Antonio. Lead sponsors running advanced solid tumors studies include Jiangsu HengRui Medicine Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd..

Browse advanced solid tumors trials by phase

Treatments under study

About Advanced Solid Tumors Clinical Trials

Looking for clinical trials for Advanced Solid Tumors? There are currently 189 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 227 trials

Recruiting
Early Phase 1

NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors

Advanced Solid Tumors
Base Therapeutics (Shanghai) Co., Ltd.18 enrolled1 locationNCT07561437
Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

Prostate CancerMelanomaSmall Cell Lung Cancer+1 more
Hangzhou DAC Biotechnology Co., Ltd.150 enrolled3 locationsNCT07177937
Recruiting
Phase 1

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Advanced Breast CancerAdvanced Solid TumorsMetastatic Pancreatic Cancer+3 more
National Cancer Institute (NCI)116 enrolled2 locationsNCT04222413
Recruiting
Phase 1Phase 2

A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer

Advanced Solid Tumors
Chong Kun Dang Pharmaceutical140 enrolled1 locationNCT07439094
Recruiting
Phase 1

A Study of MGC028 in Participants With Advanced Solid Tumors

CholangiocarcinomaColorectal CarcinomaPancreatic Carcinoma+2 more
MacroGenics124 enrolled7 locationsNCT06723236
Recruiting
Phase 1

HWS116 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company56 enrolled1 locationNCT07413328
Recruiting
Phase 1

A Study of BG-C477 in Participants With Advanced Solid Tumors

Advanced Solid Tumors
BeOne Medicines310 enrolled32 locationsNCT06596473
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc.134 enrolled22 locationsNCT06898450
Recruiting
Phase 1

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Advanced Solid Tumors
Gilead Sciences154 enrolled6 locationsNCT06532565
Recruiting
Phase 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.138 enrolled9 locationsNCT07360314
Recruiting
Phase 1

A Study of PHST001 in Advanced Solid Tumors

Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 1

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

Advanced Solid Tumors
Genmab121 enrolled5 locationsNCT07387068
Recruiting
Phase 1

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer104 enrolled10 locationsNCT06659341
Recruiting
Phase 2

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

TMB-HHistologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
ImmuneOncia Therapeutics Inc.30 enrolled4 locationsNCT06365840
Recruiting
Phase 1

A Study of PHN-012 in Patients With Advanced Solid Tumors

Pancreatic CancerColon CancerAdvanced Cancer+2 more
Pheon Therapeutics165 enrolled21 locationsNCT07127874
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled6 locationsNCT07403721
Recruiting
Phase 1

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors
Teva Branded Pharmaceutical Products R&D LLC240 enrolled11 locationsNCT06480552
Recruiting
Phase 1

A Study of BGM-2121 in Patients With Advanced Solid Tumors

Advanced Solid Tumors
BioGate Precision Medicine Corp.35 enrolled3 locationsNCT07346846
Recruiting
Phase 1Phase 2

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Advanced Solid Tumors
Ottimo Pharma Limited170 enrolled8 locationsNCT07266428